Industry
Biotechnology
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Loading...
Open
6.43
Mkt cap
277M
Volume
193K
High
6.45
P/E Ratio
-3.62
52-wk high
9.01
Low
6.25
Div yield
N/A
52-wk low
3.05
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 11:59 am
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 3:49 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 11:38 am
Portfolio Pulse from Benzinga Newsdesk
September 20, 2024 | 3:09 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 11:30 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:34 am
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 6:30 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 11:33 am
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 11:31 am
Portfolio Pulse from Benzinga Newsdesk
July 03, 2024 | 10:18 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.